Summary
34 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- It cut its dividend by 49% last year.
- Revenue fell by 5.3% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.2% a year over 5 years. Over the last 3 years it fell by 5.3% a year. For the next fiscal year analysts expect revenue to grow by 1.8%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $304.0M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 33.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.77%
You receive $0.35 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 7
- Hold 12
- Sell 1
Today's price within the analysts' price targets
The average target of $20 is 58% above today's price. 35% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Titanium Technologies 42%
- Thermal And Specialized Solutions 36%
- Advanced Performance Materials 22%
By region
- North America 46%
- Asia Pacific 21%
- EMEA 20%
- Latin America 13%
Titanium Technologies brings in 42% of revenue. Thermal And Specialized Solutions grew fastest, by 13% a year.
Segments in detail